APA (7th ed.) Citation

Phelip, J., Desrame, J., Edeline, J., Barbier, E., Terrebonne, E., Michel, P., . . . Malka, D. (2020). 52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial. Annals of Oncology, 31, S260. https://doi.org/10.1016/j.annonc.2020.08.030

Chicago Style (17th ed.) Citation

Phelip, J.M, et al. "52P Modified FOLFIRINOX Versus CISGEM as First-line Chemotherapy for Advanced Biliary Tract Cancer: Results of AMEBICA PRODIGE 38 Randomized Phase II Trial." Annals of Oncology 31 (2020): S260. https://doi.org/10.1016/j.annonc.2020.08.030.

MLA (9th ed.) Citation

Phelip, J.M, et al. "52P Modified FOLFIRINOX Versus CISGEM as First-line Chemotherapy for Advanced Biliary Tract Cancer: Results of AMEBICA PRODIGE 38 Randomized Phase II Trial." Annals of Oncology, vol. 31, 2020, p. S260, https://doi.org/10.1016/j.annonc.2020.08.030.